| Not Yet Recruiting | A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors Esophageal and/or Cardia Cancer, Melanoma, Urothelial Carcinoma (UC) | Phase 1 | 2026-06-30 |
| Not Yet Recruiting | A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX Multiple Myeloma (MM) | Phase 1 | 2026-05-27 |
| Not Yet Recruiting | A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours mCRPC or Advanced/Metastatic Solid Tumors | Phase 1 | 2026-05-25 |
| Not Yet Recruiting | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tu Advanced/Metastatic Solid Tumors | Phase 1 | 2026-05-17 |
| Not Yet Recruiting | A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Subjects Healthy Adult Male | Phase 1 | 2026-05-14 |
| Not Yet Recruiting | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients Wit SCLC, NEC | Phase 1 | 2026-04-30 |
| Not Yet Recruiting | Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo® Health Adult Subjects | Phase 1 | 2026-04-30 |
| Not Yet Recruiting | Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Adv Breast Cancer (Triple Negative Breast Cancer (TNBC)) | Phase 2 | 2026-04-25 |
| Not Yet Recruiting | A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Comb Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | 2026-04-09 |
| Not Yet Recruiting | A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Hormone Receptor Positive HER-2 Negative Breast Cancer | Phase 2 | 2026-04-01 |
| Not Yet Recruiting | Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX Advanced/Metastatic Solid Tumors | Phase 1 | 2026-03-01 |
| Not Yet Recruiting | A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placeb Squamous NSCLC | Phase 2 / Phase 3 | 2026-03-01 |
| Recruiting | A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Bre HER2 + Breast Cancer | Phase 2 / Phase 3 | 2026-02-27 |
| Not Yet Recruiting | A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastat Colon Cancer Adenocarcinoma | Phase 1 / Phase 2 | 2026-01-31 |
| Not Yet Recruiting | A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzu HER2 + Breast Cancer | Phase 2 / Phase 3 | 2026-01-27 |
| Recruiting | A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects Non Small Cell Lung Cancer | Phase 2 | 2026-01-20 |
| Not Yet Recruiting | A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Can Non Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 2 | 2026-01-14 |
| Not Yet Recruiting | A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | 2025-12-29 |
| Recruiting | A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors Advanced/Metastatic Solid Tumors, NSCLC | EARLY_Phase 1 | 2025-12-29 |
| Recruiting | Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Hepatocellular Carcinoma (HCC) | Phase 1 | 2025-11-25 |
| Recruiting | A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma | Phase 1 | 2025-09-26 |
| Recruiting | Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Su Colorectal Cancer (CRC) | Phase 2 | 2025-09-15 |
| Recruiting | Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Su Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2025-09-15 |
| Recruiting | A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combin Membranous Nephropathy, Lupus Nephritis (LN) | Phase 2 | 2025-08-05 |
| Recruiting | A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemothe SCLC, Extensive Stage | Phase 2 | 2025-06-24 |
| Recruiting | A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) Non Small Cell Lung Cancer | Phase 2 | 2025-06-09 |
| Active Not Recruiting | Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokine Cancer, mCRC | Phase 1 | 2025-06-04 |
| Not Yet Recruiting | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a Hepatocellular Carcinoma (HCC) | Phase 3 | 2025-04-30 |
| Not Yet Recruiting | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | 2025-04-27 |
| Recruiting | A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Ce Carcinoma of Head and/or Neck | Phase 2 | 2025-04-22 |
| Recruiting | A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Lo HER2-low Hormone Receptor Positive Breast Cancer | Phase 2 | 2025-04-16 |
| Recruiting | A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or In Nasopharyngeal Carcinoma (NPC) | Phase 2 | 2025-04-02 |
| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexa Newly Diagnosed Multiple Myeloma | Phase 3 | 2025-04-01 |
| Recruiting | A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Into Carcinoma, Hepatocellular | Phase 2 | 2025-03-03 |
| Recruiting | A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metas Solid Tumor Cancer, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | 2025-02-25 |
| Recruiting | A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advan Cervical Cancer, Ovarian Cancer | Phase 2 | 2025-02-20 |
| Recruiting | A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance t Esophageal Cancer | Phase 2 | 2025-01-26 |
| Recruiting | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastro Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer | Phase 3 | 2024-11-22 |
| Recruiting | A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 Carcinoma, Hepatocellular | Phase 2 | 2024-08-05 |
| Not Yet Recruiting | Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor o Solid Tumor, Adult Lymphoma | Phase 1 | 2024-06-01 |
| Completed | A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Sa IPF | Phase 1 | 2024-04-23 |
| Active Not Recruiting | A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characte EGFR Overexpression | Phase 1 | 2024-04-22 |
| Recruiting | A Study of HLX42 in Advanced/Metastatic Solid Tumors Solid Tumor and NSCLC | Phase 1 | 2024-03-14 |
| Unknown | A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects Healthy Male Volunteers | Phase 1 | 2023-11-28 |
| Recruiting | A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors Advanced/Metastatic Malignant Solid Tumors | Phase 1 | 2023-11-24 |
| Active Not Recruiting | A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combi NSCLC Stage IV | Phase 2 | 2023-07-10 |
| Completed | Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects NSCLC | Phase 1 | 2023-07-04 |
| Completed | Mass Balance Study of [14C]HLX208 in China Healthy Subjects Mass Balance Study in Healthy Subjects | Phase 1 | 2023-06-17 |
| Terminated | Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC Colorectal Cancer Metastatic | Phase 2 | 2023-06-15 |
| Unknown | HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors Solid Tumor | Phase 1 | 2023-03-30 |
| Unknown | A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive S Small-cell Lung Cancer | Phase 2 | 2023-03-29 |
| Unknown | A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Muta Non Small Cell Lung Cancer | Phase 1 / Phase 2 | 2023-02-28 |
| Unknown | A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression HLX07, nsqNSCLC, High EGFR Expression | Phase 2 | 2023-02-01 |
| Completed | A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subject Multiple Myeloma | Phase 1 | 2023-01-31 |
| Unknown | Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients COVID-19 | — | 2023-01-15 |
| Unknown | A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminar Solid Tumor, Adult | Phase 1 | 2023-01-06 |
| Unknown | Evaluate Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19 in China COVID-19 | Phase 2 | 2023-01-06 |
| Unknown | Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid SARS-CoV-2 Infection | Phase 2 / Phase 3 | 2022-12-29 |
| Active Not Recruiting | Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo Nasopharyngeal Carcinoma by AJCC V8 Stage | Phase 2 | 2022-12-14 |
| Unknown | A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors | Phase 1 | 2022-12-14 |
| Unknown | A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors Advanced/Metastatic Solid Tumors | Phase 1 | 2022-12-09 |
| Unknown | A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Sub Solid Tumor and Lymphoma | Phase 1 | 2022-12-02 |
| Active Not Recruiting | To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES- Extensive Stage Small Cell Lung Cancer | Phase 3 | 2022-11-18 |
| Withdrawn | A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the Hepatocellular Carcinoma (HCC) | Phase 3 | 2022-11-15 |
| Unknown | A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation Solid Tumor | Phase 2 | 2022-10-20 |
| Withdrawn | A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patient Cervical Cancer | Phase 3 | 2022-09-30 |
| Unknown | A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in P ESCC or Esophageal Adenosquamous Carcinoma | Phase 2 | 2022-08-25 |
| Unknown | HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma Advanced Hepatocellular Carcinoma | Phase 2 | 2022-08-01 |
| Completed | Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 Adult Solid Tumor | Phase 1 | 2022-07-26 |
| Withdrawn | A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor Advanced Solid Tumor | Phase 1 | 2022-07-18 |
| Not Yet Recruiting | Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in P CRC | Phase 2 | 2022-07-15 |
| Unknown | A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Advanced Tumors, Lymphoma, Metastatic Tumors | Phase 1 / Phase 2 | 2022-06-20 |
| Completed | A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteop Postmenopausal | Phase 3 | 2022-06-17 |
| Unknown | The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) Cutaneous Squamous Cell Carcinoma | Phase 2 | 2022-06-15 |
| Unknown | HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors Locally Advanced or Metastatic Solid Tumors, Squamous-cell Non-small Cell Lung Cancer | Phase 1 | 2022-06-03 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Rad Limited-Stage Small Cell Lung Cancer | Phase 3 | 2022-05-17 |
| Unknown | HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors Locally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2022-05-03 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positi Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer | Phase 3 | 2022-04-25 |
| Unknown | The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation Metastatic Colorectal Cancer, mCRC | Phase 2 | 2022-03-23 |
| Unknown | HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) | Phase 2 | 2022-03-23 |
| Unknown | A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation Advanced Melanoma | Phase 2 | 2022-03-21 |
| Unknown | A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC Squamous Non-small-cell Lung Cancer | Phase 2 | 2022-01-18 |
| Unknown | HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors Solid Tumor | Phase 1 | 2022-01-05 |
| Unknown | The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After Fir Brain Tumor, Primary | Phase 2 | 2021-12-23 |
| Unknown | The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation Anaplastic Thyroid Cancer, ATC | Phase 1 / Phase 2 | 2021-12-10 |
| Unknown | The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (EC Langerhans Cell Histiocytosis, Erdheim-Chester Disease, LCH | Phase 2 | 2021-12-06 |
| Unknown | A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mu NSCLC | Phase 2 | 2021-11-15 |
| Completed | Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD Age Related Macular Degeneration | Phase 3 | 2021-11-01 |
| Completed | A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Solid Tumor, Adult, Lymphoma | Phase 1 | 2021-10-11 |
| Active Not Recruiting | Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab Gastric Cancer | Phase 2 | 2021-09-29 |
| Unknown | The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF CRC | Phase 2 | 2021-08-11 |
| Completed | Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD Age Related Macular Degeneration | Phase 1 / Phase 2 | 2021-07-15 |
| Completed | A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD Age Related Macular Degeneration | Phase 3 | 2021-07-01 |
| Recruiting | A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Ch Metastatic Colorectal Cancer | Phase 2 / Phase 3 | 2021-03-10 |
| Completed | A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chines Healthy | Phase 1 | 2021-03-02 |
| Withdrawn | Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers COVID-19 | Phase 1 | 2020-12-09 |
| Completed | Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects Healthy Male Volunteers | Phase 1 | 2020-11-03 |
| Withdrawn | Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lympho CD20-positive Follicular Lymphoma, With Low Tumour Burden | Phase 3 | 2020-10-01 |
| Unknown | Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tu Head and Neck Squamous Cell Carcinoma | Phase 2 | 2020-07-29 |
| Completed | Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male Subjects Healthy Male Volunteers | Phase 1 | 2020-07-01 |
| Not Yet Recruiting | to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With C Triple Negative Breast Cancer | Phase 3 | 2020-04-17 |
| Unknown | A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients W Cervical Cancer | Phase 2 | 2020-03-10 |
| Unknown | A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant Gastric Cancer | Phase 3 | 2019-12-12 |
| Unknown | A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carbo Carcinoma, Non-Small-Cell Lung | Phase 3 | 2019-12-02 |
| Unknown | A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocel Hepatocellular Carcinoma | Phase 2 | 2019-09-24 |
| Completed | A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC Extensive Stage Small Cell Lung Cancer | Phase 3 | 2019-09-12 |
| Unknown | A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Lin Squamous Non Small Cell Lung Cancer | Phase 3 | 2019-08-14 |
| Completed | Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpress Solid Tumor | Phase 1 | 2019-07-31 |
| Recruiting | A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to MSI-H Solid Malignant Tumor | Phase 2 | 2019-07-15 |
| Unknown | A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Esophageal Squamous Cell Carcinoma | Phase 3 | 2019-06-19 |
| Terminated | Compare Pharmacokinetic, Safety, Tolerability and Immunogenicity of HLX12 and Ramucirumab in Healthy Male Adul Healthy Male Volunteers | Phase 1 | 2019-06-06 |
| Unknown | A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX1 Solid Tumor | Phase 1 | 2018-11-27 |
| Completed | The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tu Advanced Solid Tumors | Phase 1 / Phase 2 | 2018-08-08 |
| Completed | A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid T Advanced Solid Tumors | Phase 1 | 2018-08-07 |
| Completed | Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis Moderately to Severely Active Rheumatoid Arthritis | Phase 3 | 2018-05-28 |
| Completed | A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or Metastatic Colorectal Cancer (mCRC) | Phase 3 | 2018-04-09 |
| Completed | Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis Plaque Psoriasis | Phase 3 | 2017-10-27 |
| Completed | Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male Subjects Healthy Male Subjects | Phase 1 | 2017-04-21 |
| Completed | Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects Immune System Disorder | Phase 1 | 2017-01-12 |
| Completed | Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressin Breast Cancer | Phase 3 | 2016-11-01 |
| Completed | A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Ri Rheumatoid Arthritis | Phase 1 / Phase 2 | 2016-02-01 |
| Completed | Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination W B-cell Non Hodgkin's Lymphoma | Phase 3 | 2015-10-01 |
| Completed | A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(U.S. and German Sourced) in Healthy Chinese Ma Healthy | Phase 1 | 2015-09-16 |
| Completed | A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-ce B-cell Non Hodgkin's Lymphoma | Phase 1 / Phase 2 | 2014-10-01 |
| Completed | A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas B-cell Lymphomas | Phase 1 | 2014-05-04 |